AAAAAA
Results:
1-8
|
Results: 8
Authors:
Boaz, M
Green, M
Fainauru, M
Smetana, S
Citation: M. Boaz et al., Oxidative stress and cardiovascular disease in hemodialysis, CLIN NEPHR, 55(2), 2001, pp. 93-100
Authors:
Boaz, M
Smetana, S
Green, MS
Citation: M. Boaz et al., Vitamin E supplementation - Reply, LANCET, 357(9256), 2001, pp. 632-633
Authors:
Boaz, M
Smetana, S
Weinstein, T
Matas, Z
Gafter, U
Iaina, A
Knecht, A
Weissgarten, Y
Brunner, D
Fainaru, M
Green, MS
Citation: M. Boaz et al., Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial, LANCET, 356(9237), 2000, pp. 1213-1218
Authors:
Boaz, M
Matas, Z
Biro, A
Katzir, Z
Green, M
Fainaru, M
Smetana, S
Citation: M. Boaz et al., Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients, AM J KIDNEY, 34(3), 1999, pp. 438-444
Authors:
Dan, M
Poch, F
Leibson, L
Smetana, S
Priel, I
Citation: M. Dan et al., Rectal colonization with vancomycin-resistant enterococci among high-risk patients in an Israeli hospital, J HOSP INF, 43(3), 1999, pp. 231-238
Authors:
Nyska, A
Haseman, JK
Hailey, JR
Smetana, S
Maronpot, RR
Citation: A. Nyska et al., The association between severe nephropathy and pheochromocytoma in the male F344 rat - The National Toxicology Program experience, TOX PATHOL, 27(4), 1999, pp. 456-462
Authors:
Boaz, M
Matas, Z
Biro, A
Katzir, Z
Green, M
Fainaru, M
Smetana, S
Citation: M. Boaz et al., Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis, KIDNEY INT, 56(3), 1999, pp. 1078-1083
Authors:
Mandelberg, A
Krupnik, Z
Houri, S
Smetana, S
Gilad, E
Matas, Z
Priel, IE
Citation: A. Mandelberg et al., Salbutamol metered-dose inhaler with spacer for hyperkalemia - How fast? How safe?, CHEST, 115(3), 1999, pp. 617-622
Risultati:
1-8
|